Elite Pharmaceuticals, Inc. (OTCQB: ELTP) reported consolidated revenue of $40.1 million for the second quarter of fiscal 2027 ended September 30, 2026, up $3.8 million, or approximately 10.4%, from the prior-year period.
Net income attributable to common shareholders was $17.3 million, while income from operations totaled $9.9 million, up approximately 21% year over year.
- Revenue growth was primarily attributed to increased sales of Elite-label amphetamine and naltrexone product lines.
- Income from operations increased by $1.7 million from the same quarter of the prior fiscal year.
- Management will host a conference call on November 13, 2026, at 11:30 a.m. EST.
$ELTP Insider Trading Activity
$ELTP insiders have traded $ELTP stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ELTP stock by insiders over the last 6 months:
- BARRY H DASH has made 2 purchases buying 130,000 shares for an estimated $34,590 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ELTP Hedge Fund Activity
We have seen 0 institutional investors add shares of $ELTP stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KELLEHER FINANCIAL ADVISORS removed 1,000 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $241
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
